Pfizer: COVID-19 Antiviral Pill Reduces Hospitalization, Death by Nearly 90%


Pfizer plans to turn over the data to the Food and Drug Administration for its emergency use authorization application “as soon as possible.” The data has not been published or peer reviewed.

“Today’s news is a real game-changer in the global efforts to halt the devastation of this pandemic. These data suggest that our oral antiviral candidate, if approved or authorized by regulatory authorities, has the potential to save patients’ lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations,” Pfizer CEO Albert Bourla said in a statement.

Most COVID-19 treatments currently in use require an IV, so an easy-to-take pill could help keep people out of hospitals.

Leave a Reply

Your email address will not be published.